ENDRA Validates Portable TAEUS Liver with 0.90 MRI Correlation and AUROC up to 0.99
ENDRA Life Sciences’ multi-site trial of TAEUS Liver on 64 U.S. and Canadian patients showed a 0.90 correlation with MRI-PDFF, AUROC of 0.95–0.99 and mean error of ~3%, with ICC of 0.89 across operators. The portable device costs under $200 per scan and delivers consistent readings independent of BMI.
1. Multi-Site Clinical Validation
ENDRA’s TAEUS Liver system was tested on 64 patients across multiple U.S. and Canadian sites, including London, Ontario. Results showed a strong correlation to MRI-PDFF (r=0.90), diagnostic AUROC between 0.95 and 0.99, a mean error of approximately 3%, and an intraclass correlation coefficient of 0.89 across independent operators.
2. Portable, Low-Cost Point-of-Care Solution
TAEUS Liver delivers MRI-like thermoacoustic fat fraction measurements at the point of care, with per-scan costs under $200—under 8% of typical MRI-PDFF exams. Approximately 90% of measurements fell within 5% of MRI values, with no dependence on patient BMI or body habitus.
3. Clinical and Market Implications
High reproducibility and consistent performance across diverse sites position TAEUS Liver for widespread use in liver fat assessment. The technology could support frequent monitoring for over two billion people at risk of MASLD and aid pharmaceutical firms in patient recruitment and treatment monitoring.